Is There A Cure For Old Age?

Longevity Therapeutics Developers Aim To Find Out

Investment and research into the science of aging – and therapeutics that could slow down or even reverse the aging process – are ramping up. Past clinical failures have given way to new and focused approaches that aim to lengthen “healthspan,” turning the last years of life into the best years of life.     

Old age

In his forthcoming book, titled The Science and Technology of Growing Young, Sergey Young, a venture capitalist and founder of the $100m Longevity Vision Fund, declares that “aging is a disease,” the implication being that it can, and should, be treated.

The Longevity Vision Fund, which focuses exclusively on anti-aging technologies, drugs, devices and diagnostics, was created to help catalyze a...

More from Innovation

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

More from In Vivo